Causes of polymyxin treatment failure and new derivatives to fill the gap

Chiu, Selena; Hancock, Anna M.; Schofner, Bob W.; Sniezek, Katherine J.; Soto-Echevarria, Nashaly; Leon, Gabrielle; Sivaloganathan, Darshan M.; Wan, Xuanqing; Brynildsen, Mark P.

doi:10.1038/s41429-022-00561-3

Cited by 6 publications

(3 citation statements)

References 175 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A cationic polypeptide rattles the cell membrane through a detergentlike mechanism. Colistimethate sodium is hydrolyzed in aqueous solutions, leading to a composite fusion of sulfomethylated metabolites and Colistin (Michalopoulos and Karatza 2010;Michalopoulos and Falagas 2011;Ayoub Moubareck 2020;Chiu et al 2022)…”

Section: Structure and Pharmacodynamics Properties Of Colistinmentioning

confidence: 99%

Colistin the last resort drug in 21st century antibiotics to combat Multidrug resistance superbugs

Sahoo,

Mohanty,

Routray

et al. 2023

J Exp Bio & Ag Sci

View full text Add to dashboard Cite

Polymyxin' E' (Colistin) is considered the last resort therapy against Multidrug resistance (MDR) bacteria, mainly Klebsiella peumoniae, Pseudomonas aeruginosa, Acinetobacter baumannii, and Escherichia coli and play a critical role in causing life-threatening infection, and their prevalence is increasing as a big concern globally. Apart from immunological adaptation, chromosomal mutations and plasmid-mediated genes are mostly associated with this resistance at the molecular level. Therefore, the current review extensively focused on Colistin as a drug in 21st-century antibiotics, the activities spectrum with diverse resistance mechanisms of bacteria against Colistin, and emerging approaches of Colistin from discovery to tackling MDR. In the study, we got to know about the challenges and new developments with old weapons like phage therapy as well as new approaches like Phage display and drug repurposing, in addition to the chromosomal and plasmid-mediated genes that play a role in antimicrobial resistance (AMR). The present study would provide insight into the prognostic aspect of combating MDR.

show abstract

Section: Structure and Pharmacodynamics Properties Of Colistinmentioning

confidence: 99%

Colistin the last resort drug in 21st century antibiotics to combat Multidrug resistance superbugs

Sahoo,

Mohanty,

Routray

et al. 2023

J Exp Bio & Ag Sci

View full text Add to dashboard Cite

show abstract

“…5,6 However, next-generation sequencing has revealed that microbial genomes still harbor a huge underexplored biosynthetic potential of bacteria. 7,8 Polymyxins are a very promising class of antibiotics that are used as a last line of therapy against MDR pathogens 9 and are primarily produced by Paenibacillus species. With resistance against polymyxins inevitably increasing, we urgently need to search for potent alternatives.…”

Section: ■ Introductionmentioning

confidence: 99%

“…Polymyxins are a very promising class of antibiotics that are used as a last line of therapy against MDR pathogens 9 and are primarily produced by Paenibacillus species. With resistance against polymyxins inevitably increasing, we urgently need to search for potent alternatives.…”

Section: Introductionmentioning

confidence: 99%

Discovery and Derivatization of Tridecaptin Antibiotics with Altered Host Specificity and Enhanced Bioactivity

Machushynets,

Al Ayed,

Terlouw

et al. 2024

ACS Chem. Biol.

View full text Add to dashboard Cite

The prevalence of multidrug-resistant (MDR) pathogens combined with a decline in antibiotic discovery presents a major challenge for health care. To refill the discovery pipeline, we need to find new ways to uncover new chemical entities. Here, we report the global genome mining-guided discovery of new lipopeptide antibiotics tridecaptin A 5 and tridecaptin D, which exhibit unusual bioactivities within their class. The change in the antibacterial spectrum of Oct-TriA 5 was explained solely by a Phe to Trp substitution as compared to Oct-TriA 1 , while Oct-TriD contained 6 substitutions. Metabolomic analysis of producer Paenibacillus sp. JJ-21 validated the predicted amino acid sequence of tridecaptin A 5 . Screening of tridecaptin analogues substituted at position 9 identified Oct-His9 as a potent congener with exceptional efficacy against Pseudomonas aeruginosa and reduced hemolytic and cytotoxic properties. Our work highlights the promise of tridecaptin analogues to combat MDR pathogens.

show abstract

Clinical relevance, mechanisms, and evolution of polymyxin B heteroresistance carbapenem-resistant Klebsiella pneumoniae: A genomic, retrospective cohort study

Luo,

Xu,

Wang

et al. 2024

Clinical Microbiology and Infection

View full text Add to dashboard Cite

Causes of polymyxin treatment failure and new derivatives to fill the gap

Cited by 6 publications

References 175 publications

Colistin the last resort drug in 21st century antibiotics to combat Multidrug resistance superbugs

Colistin the last resort drug in 21st century antibiotics to combat Multidrug resistance superbugs

Discovery and Derivatization of Tridecaptin Antibiotics with Altered Host Specificity and Enhanced Bioactivity

Clinical relevance, mechanisms, and evolution of polymyxin B heteroresistance carbapenem-resistant Klebsiella pneumoniae: A genomic, retrospective cohort study

Contact Info

Product

Resources

About